卡那奴单抗对比安慰剂联合一线帕博利珠单抗加化疗治疗晚期非小细胞肺癌:CANOPY-1试验结果
CANOPY-1是一项III期随机双盲研究,比较卡那奴单抗(200 mg皮下注射每3周)与安慰剂联合帕博利珠单抗(200 mg静脉注射每3周)及铂类双药化疗一线治疗无EGFR或ALK突变的晚期/转移性非小细胞肺癌。共643例患者随机分配至卡那奴单抗组(n=320)或安慰剂组(n=323)。中位随访6.5个月时,中位无进展生存期两组均为6.8个月(HR 0.85;95%CI 0.67-1.09;P=0.102);中位随访21.2个月时,中位总生存期卡那奴单抗组20.8个月 vs 安慰剂组20.2个月(HR 0.87;95%CI 0.70-1.10;P=0.123)。结论:在帕博利珠单抗加化疗基础上加用卡那奴单抗未延长无进展生存期或总生存期。
要点
- 卡那奴单抗联合帕博利珠单抗加化疗未显著延长晚期NSCLC患者的无进展生存期(HR 0.85;95%CI 0.67-1.09;P=0.102)。
- 卡那奴单抗联合组与安慰剂组总生存期无显著差异(HR 0.87;95%CI 0.70-1.10;P=0.123)。
- 卡那奴单抗组报告了更高频率的中性粒细胞减少和ALT升高(≤2级),感染率两组相当。
核心结论
- 在帕博利珠单抗加化疗基础上加用卡那奴单抗未延长晚期非小细胞肺癌患者的无进展生存期或总生存期。
研究设计与样本
- CANOPY-1是一项III期随机双盲研究,比较卡那奴单抗(200 mg皮下注射每3周)与安慰剂联合帕博利珠单抗(200 mg静脉注射每3周)及铂类双药化疗一线治疗无EGFR或ALK突变的晚期/转移性非小细胞肺癌。
- 共643例患者随机分配至卡那奴单抗组(n=320)或安慰剂组(n=323)。
- 主要终点为无进展生存期和总生存期,次要终点包括总缓解率、安全性和患者报告结局。
主要发现
- 中位随访6.5个月时,卡那奴单抗组中位无进展生存期6.8个月 vs 安慰剂组6.8个月(HR 0.85;95%CI 0.67-1.09;P=0.102)。
- 中位随访21.2个月时,卡那奴单抗组中位总生存期20.8个月 vs 安慰剂组20.2个月(HR 0.87;95%CI 0.70-1.10;P=0.123)。
- 卡那奴单抗联合组未观察到非预期安全信号,感染率治疗组与对照组相当。
- 卡那奴单抗组报告了更高频率的中性粒细胞减少和ALT升高(≤2级)。
- 基线C反应蛋白和IL-6水平较高与较短的无进展生存期和总生存期相关。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: The addition of checkpoint inhibitors to first-line treatment has prolonged survival of patients with non-small-cell lung cancer (NSCLC), but prognosis remains poor, with new treatment options needed. Canakinumab, a human, monoclonal anti-interleukin (IL)-1β antibody, has potential to enhance the activity of PD-L1 inhibitors and chemotherapy (CT) by inhibiting protumor inflammation. METHODS: CANOPY-1 was a phase III, randomized, double-blind study comparing canakinumab (200 mg subcutaneously once every 3 weeks) versus placebo, both combined with pembrolizumab (200 mg intravenously once every 3 weeks) and platinum-based doublet CT, as first-line treatment for advanced/metastatic NSCLC without EGFR or ALK mutations. The primary end points were progression-free survival (PFS) and overall survival (OS). The secondary endpoints included overall response rate, safety, and patient-reported outcomes. RESULTS: Overall, 643 patients were randomly assigned to canakinumab (n = 320) or placebo (n = 323). With a median study follow-up of 6.5 months, the median PFS was 6.8 months with canakinumab versus 6.8 months with placebo (hazard ratio [HR], 0.85; 95% CI, 0.67 to 1.09; P = .102). With a median study follow-up of 21.2 months, the median OS was 20.8 months with canakinumab versus 20.2 months with placebo (HR, 0.87; 95% CI, 0.70 to 1.10; P = .123). No unexpected safety signals were observed for canakinumab combination. Infection rates were comparable between treatment and control arms. A higher frequency of neutropenia and ALT increase (grade ≤2) were reported in the treatment arm. Higher baseline C-reactive protein and IL-6 levels were associated with shorter PFS and OS. Patients treated with canakinumab had clinically meaningful delays in deterioration of lung cancer symptoms, including chest pain and coughing per LC13 and dyspnea per LC13 and C30. CONCLUSION: The addition of canakinumab to first-line pembrolizumab and CT did not prolong PFS or OS in patients with NSCLC.
引用
- Tan DSW, Felip E, de Castro G, et al. Canakinumab Versus Placebo in Combination With First-Line Pembrolizumab Plus Chemotherapy for Advanced Non-Small-Cell Lung Cancer: Results From the CANOPY-1 Trial. J Clin Oncol. 2023. PMID: 38039427. doi:10.1200/JCO.23.00980
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。